ImmunoGen Q4 Earnings Preview: All eyes on FORWARD trial update
ImmunoGen Q4 Earnings Preview: All eyes on FORWARD trial update
ImmunoGen (NASDAQ: IMGN) is slated to report its fourth quarter 2018 results tomorrow before the bell. The most anticipated update from the biotech firm would be related to its lead drug mirvetuximab soravtansine’s Phase 3 FORWARD trial progress. Investors would like to know whether the firm is on track to release data in the first half of 2019.
It’s worth noting that the biotech firm doesn’t…
View On WordPress













